Pulmonology
COPD Pathophysiology
Inflammation plus emphysema — irreversible airflow limitation, year by year
Chronic obstructive pulmonary disease combines airway inflammation with alveolar destruction. Post-bronchodilator FEV1/FVC under 0.70 confirms airflow limitation. Smoking causes most cases; α1-antitrypsin deficiency causes a small but distinct minority. The 4th leading cause of death globally.
- Global mortality rank4th leading cause of death
- Diagnostic criterionFEV1/FVC < 0.70 post-bronchodilator
- Dominant causeTobacco smoke (~85% in high-income)
- Inflammation typeNeutrophilic, CD8+ T-cell driven
- Mortality-reducing therapiesCessation, O₂, NIV (in selected)
- α1-AT deficiency share1-3% of COPD cases
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
The two-pathology disease
COPD is not one disease but two overlapping ones: chronic bronchitis (defined clinically as a productive cough for ≥3 months in 2 consecutive years) and emphysema (defined pathologically as permanent enlargement of distal airspaces with destruction of alveolar walls). Most COPD patients have both — the proportions vary, producing the historical bedside types: the "blue bloater" with bronchitis-predominant disease (hypoxic, hypercapnic, edematous from cor pulmonale) and the "pink puffer" with emphysema-predominant disease (thin, tachypneic, well-saturated until late). Modern phenotyping uses spirometry, imaging, and biomarkers rather than these caricatures, but the underlying biology persists.
What unites them is irreversibility. Asthma airways can return to normal after a bronchodilator; COPD airways cannot. The structural changes — fibrotic narrowing of small airways, loss of alveolar attachments, hypertrophied smooth muscle, hyperplastic goblet cells — are permanent. Bronchodilators in COPD relax superimposed reversible tone but cannot restore lost lung tissue. This is the central management implication: COPD is treated by preventing further loss, not reversing past damage.
The protease-antiprotease imbalance
The mechanistic core of emphysema is a tipping point in the lung's normal protein turnover. Inflammatory cells — neutrophils, macrophages, CD8+ lymphocytes — secrete proteases (neutrophil elastase, MMP-9, MMP-12, cathepsins) that degrade elastin, collagen, and proteoglycans in alveolar walls. Healthy lung is protected by antiproteases, principally α1-antitrypsin (AAT) made by the liver and secreted into plasma. Cigarette smoke shifts the balance two ways simultaneously: more proteases (inflammation) and less effective antiproteases (oxidative inactivation of AAT). Years of even mild imbalance compound — by the time symptoms develop, 30-40% of lung function is irrecoverably lost.
Why airflow is limited
Three structural changes converge:
- Small airway narrowing. Bronchioles less than 2 mm in diameter develop wall inflammation, peribronchial fibrosis, mucus plugs, and goblet cell metaplasia. These airways contribute the majority of the resistance increase in COPD.
- Loss of elastic recoil. Destroyed alveolar walls no longer tether the airways open during exhalation. The driving pressure pushing air out of the lung is the elastic recoil pressure — reduce it and exhalation slows.
- Dynamic airway collapse. Without alveolar attachments, small airways collapse during forced exhalation as intrathoracic pressure compresses them — the equal-pressure point moves upstream into smaller airways with each subsequent breath, trapping air distally.
Worked clinical example
A 64-year-old man, 45 pack-year smoker, presents with three years of progressive exertional dyspnea — now unable to walk a single flight of stairs without resting. Productive cough most mornings for over a decade. Examination: barrel chest, prolonged expiratory phase, distant breath sounds, mild expiratory wheezing, no peripheral edema. SpO₂ 91% on room air, BMI 22.
Spirometry: FEV1 1.05 L (38% predicted), FVC 2.40 L (72% predicted), FEV1/FVC 0.44. Post-bronchodilator: FEV1 1.12 L (only 7% improvement — not significantly reversible). Confirms GOLD 3 (severe) COPD. Chest CT shows centrilobular emphysema predominantly upper lobes. Arterial blood gas on room air: pH 7.38, PaCO₂ 48, PaO₂ 62 — mild compensated hypercapnia. CAT score 23 (high symptom burden).
Management plan: smoking cessation counseling and varenicline (the single most important intervention). LABA + LAMA combination inhaler (e.g., umeclidinium-vilanterol) as the foundation; add ICS only if blood eosinophils ≥300 or frequent exacerbations. Pulmonary rehabilitation referral. Influenza, pneumococcal (PCV20), and COVID vaccinations. Long-term oxygen therapy not yet indicated (PaO₂ >55). Reassess in 3 months. Two years later, after stopping smoking, his FEV1 decline approaches that of a non-smoker — the disease cannot be reversed, but its trajectory can be.
Chronic bronchitis vs emphysema
| Feature | Chronic bronchitis | Emphysema |
|---|---|---|
| Definition | Productive cough ≥3 months for 2 years | Permanent alveolar enlargement with wall destruction |
| Dominant pathology | Airway wall thickening, mucus hypersecretion | Alveolar wall destruction, loss of elastic recoil |
| Body habitus | "Blue bloater" — overweight, cyanotic, edematous | "Pink puffer" — thin, hyperinflated, well-saturated |
| Hypoxia / hypercapnia | Earlier, more severe | Later, often only at end-stage |
| CXR / CT | Increased markings, prominent vessels | Hyperinflation, bullae, parenchymal destruction |
| Cor pulmonale | Common | Less common until end-stage |
| Diffusion capacity (DLCO) | Normal or mildly reduced | Markedly reduced (less surface area) |
Why COPD matters
- Mortality. COPD is the 4th-leading global cause of death, accounting for ~3.2 million deaths annually.
- Preventable. Smoking cessation at any age slows decline; quitting before age 40 nearly normalizes life expectancy.
- Care cost. COPD exacerbations are among the most common reasons for hospital admission in adults >65.
- Comorbidity nexus. Cardiovascular disease, lung cancer, depression, osteoporosis, and metabolic syndrome cluster with COPD.
- Underdiagnosis. Roughly half of COPD cases are undiagnosed; case-finding spirometry in symptomatic smokers is high-yield.
- Pulmonary rehabilitation. One of the most cost-effective interventions in chronic disease — large gains in quality of life and exercise tolerance.
- Health equity. Indoor biomass smoke from cooking fires causes COPD in non-smoking women across low-income countries — a major global health priority.
Common misconceptions
- "You can't get COPD if you've never smoked." 15-20% of COPD occurs in never-smokers — biomass exposure, occupational dust, α1-AT deficiency, and severe childhood respiratory infections.
- "Oxygen kills COPD patients." Targeted O₂ to SpO₂ 88-92% is safe; the worry is uncontrolled high-flow O₂ in chronic CO₂ retainers, not therapeutic oxygen itself.
- "Inhaled steroids are the cornerstone, like asthma." In COPD, ICS is added only for high exacerbation risk or elevated eosinophils; bronchodilators come first.
- "COPD only worsens — no point treating early." Smoking cessation, vaccination, and pulmonary rehab slow decline and improve quality of life even in mild disease.
- "Bronchodilator response separates asthma from COPD." Many COPD patients have some reversibility; asthma-COPD overlap is a real entity.
- "FEV1 alone defines severity." GOLD now combines FEV1 with symptoms (CAT, mMRC) and exacerbation history to set treatment intensity.
Frequently asked questions
How does smoking actually destroy the lung?
Cigarette smoke recruits neutrophils, macrophages, and CD8+ T cells into the airways. These cells release proteases — neutrophil elastase, matrix metalloproteinases — that digest elastin and other connective-tissue proteins in alveolar walls. The lung's natural defenses, especially α1-antitrypsin, are overwhelmed and oxidatively inactivated. Years of imbalance between protease activity and antiprotease defense leave alveolar walls thinned, fragmented, and unable to recoil. In the airways, the same inflammation thickens the wall, hypertrophies smooth muscle, and produces excess mucus from goblet cells and enlarged submucosal glands. Together: airway narrowing + parenchymal destruction = airflow limitation.
What is the FEV1/FVC criterion and why 0.70?
Forced expiratory volume in 1 second (FEV1) divided by forced vital capacity (FVC) measures whether the lung can empty quickly. In healthy adults the ratio is typically 0.75-0.85. The GOLD criterion sets a fixed cutoff of <0.70 post-bronchodilator as confirming airflow limitation. The choice of 0.70 is pragmatic — simple and reproducible — but it overdiagnoses COPD in the elderly (whose ratio falls with age) and underdiagnoses in younger adults. Some societies prefer the lower limit of normal (5th percentile) instead. Severity is then graded by absolute FEV1 percent predicted: GOLD 1 (≥80%), GOLD 2 (50-79%), GOLD 3 (30-49%), GOLD 4 (<30%).
Why do COPD patients trap air?
Two reasons. First, narrowed airways increase resistance to airflow — the patient cannot exhale all of their tidal volume before the next breath begins. Second, lost elastic recoil from emphysematous destruction reduces the lung's natural ability to deflate. Small airways without surrounding alveolar tethering collapse during exhalation (dynamic airway collapse). The result: end-expiratory lung volume rises above functional residual capacity (FRC), the diaphragm flattens, the chest wall expands into the 'barrel chest' configuration, and inspiratory muscles work mechanically disadvantaged. Dyspnea-on-exertion follows because the patient breathes near total lung capacity with little reserve.
How are COPD and asthma different?
Both are obstructive, but their biology and behavior diverge. Asthma is typically eosinophilic, Th2-driven, with reversible airflow obstruction (FEV1 rises ≥12% with bronchodilator), often in non-smoking patients of any age, with marked diurnal symptom variability and bronchial hyperresponsiveness to triggers. COPD is neutrophilic, CD8-driven, with persistent and only partially reversible airflow obstruction, typically in smokers >40 years old, with stable daily symptoms punctuated by exacerbations. Asthma-COPD overlap exists — patients with features of both — and benefits from ICS-LABA combination therapy. Inhaled corticosteroids, the cornerstone of asthma management, have a much smaller role in COPD.
What treatments actually change outcomes?
Three interventions reduce mortality: smoking cessation (the only one that alters disease trajectory), long-term oxygen therapy in chronic hypoxemia (PaO₂ ≤55 mmHg or 55-59 with cor pulmonale), and noninvasive ventilation in chronic hypercapnic respiratory failure. Bronchodilators (LABA + LAMA, with or without ICS) improve symptoms, exercise tolerance, and exacerbations but not mortality directly. Pulmonary rehabilitation produces durable improvements in dyspnea and quality of life. Vaccination — influenza, pneumococcal, RSV, COVID — prevents exacerbations. Lung volume reduction (surgical or endoscopic valves) helps selected upper-lobe predominant emphysema. Lung transplant is the last resort for end-stage disease.
What about α1-antitrypsin deficiency?
α1-antitrypsin (AAT) is the dominant serpin inhibitor of neutrophil elastase. Hereditary deficiency — most commonly the PiZZ genotype — leaves the lung's protease-antiprotease balance tipped toward destruction. AAT deficiency accounts for 1-3% of COPD cases but produces a distinct phenotype: panlobular emphysema (uniform destruction across the acinus, not just centrilobular), lower-lobe predominance, onset in non-smokers in their 40s and dramatic acceleration in smokers, and frequent liver involvement from misfolded Z-protein retention in hepatocytes (cirrhosis, hepatocellular carcinoma). All COPD patients <45 or with lower-lobe disease should be screened. IV AAT augmentation therapy slows lung function decline in selected patients.
What is a COPD exacerbation?
Acute worsening of respiratory symptoms — increased dyspnea, increased sputum, increased sputum purulence — beyond day-to-day variability, requiring change in therapy. Common triggers: viral infection (rhinovirus, RSV, influenza), bacterial superinfection (H. influenzae, S. pneumoniae, M. catarrhalis, Pseudomonas in severe disease), and air pollution. Standard treatment: short-acting bronchodilators, systemic corticosteroids (prednisone 40 mg × 5 days), antibiotics if increased sputum purulence (azithromycin, doxycycline, or amoxicillin-clavulanate), and noninvasive ventilation for hypercapnic respiratory failure. Each severe exacerbation accelerates lung function decline; preventing them is a primary management goal.